A critical evaluation of the therapeutic range of indinavir
- PMID: 12086558
- DOI: 10.1345/aph.1A467
A critical evaluation of the therapeutic range of indinavir
Abstract
Objective: To provide a summary of the patient population, study characteristics, and important findings of the key studies in the literature evaluating concentration-effect relationships and the therapeutic range for indinavir.
Data sources: Literature search strategy involved using MEDLINE (1966-July 2001) and AIDSLINE (MEDSCAPE) databases (up to July 2001). Reference lists from primary literature and review articles were also examined, and conference abstracts were obtained.
Study selection: English-language articles were considered suitable for review if the clinical trials in HIV patients reported on concentration-effect relationships and/or pharmacokinetic breakpoints or threshold concentrations. A search of the literature identified 20 peer-reviewed references from 18 separate studies including journal articles and conference abstracts.
Data extraction: The targeted pharmacokinetic parameters and breakpoint values, the rationale for their selection or method of identification, and other study details and limitations were summarized.
Discussion: This article highlights the heterogeneity of studies evaluating the therapeutic range of indinavir and provides a summary of important findings of the key studies in the literature evaluating concentration-effect relationships and therapeutic range. Tables are provided to enable clinicians to make use of currently available information on the therapeutic range of indinavir.
Conclusions: There is insufficient evidence to recommend a general therapeutic range for indinavir. Future investigations should incorporate both pharmacokinetics and pharmacodynamics in order to define a broadly applicable therapeutic range.
Similar articles
-
[Evidence-based therapeutic drug monitoring for indinavir].Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Therapie. 2011. PMID: 21819808 Review. French.
-
Role of therapeutic drug monitoring for protease inhibitors.Ann Pharmacother. 2001 Jun;35(6):745-54. doi: 10.1345/aph.10249. Ann Pharmacother. 2001. PMID: 11408994 Review.
-
Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.Am J Ther. 2017 Jul/Aug;24(4):e405-e418. doi: 10.1097/MJT.0000000000000294. Am J Ther. 2017. PMID: 26291590
-
Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.Ann Pharmacother. 2002 Apr;36(4):702-6. doi: 10.1345/aph.1A202. Ann Pharmacother. 2002. PMID: 11918523 Review.
-
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.Fundam Clin Pharmacol. 2005 Jun;19(3):373-83. doi: 10.1111/j.1472-8206.2005.00315.x. Fundam Clin Pharmacol. 2005. PMID: 15910662 Clinical Trial.
Cited by
-
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Antimicrob Agents Chemother. 2004 Nov;48(11):4200-8. doi: 10.1128/AAC.48.11.4200-4208.2004. Antimicrob Agents Chemother. 2004. PMID: 15504842 Free PMC article. Clinical Trial.
-
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32. doi: 10.1128/AAC.48.9.3226-3232.2004. Antimicrob Agents Chemother. 2004. PMID: 15328077 Free PMC article. Clinical Trial.
-
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.Eur J Clin Pharmacol. 2009 Jul;65(7):667-78. doi: 10.1007/s00228-009-0660-5. Epub 2009 May 14. Eur J Clin Pharmacol. 2009. PMID: 19440701 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical